In Silico Identification of Natural Product-Based Inhibitors Targeting IL-1β/IL-1R Protein–Protein Interface
Authors:
- Ting-Ting LiuTLTing-Ting Liu
- Yan-Kun ChenYCYan-Kun Chen
- Muhammad AdilMAMuhammad Adil
- Mazen AlmehmadiMAMazen Almehmadi
- Fahad M. AlshabrmiFAFahad M. Alshabrmi
- Mamdouh AllahyaniMAMamdouh Allahyani
- Ahad Amer AlsaiariAAAhad Amer Alsaiari
- Pei LiuPLPei Liu
- Muhammad Raheel KhanMKMuhammad Raheel Khan
- Qinghua PengQPQinghua Peng
Open Access
Abstract
IL-1β mediates inflammation and regulates immune responses, cell proliferation, and differentiation. Dysregulation of IL-1β is linked to inflammatory and autoimmune diseases. Elevated IL-1β levels are found in patients with severe COVID-19, indicating its excessive production may worsen the disease. Also, dry eye disease patients show high IL-1β levels in tears and conjunctival epithelium. Therefore, IL-1β signaling is a potential therapeutic targeting for COVID-19 and aforementioned diseases. No small-molecule IL-1β inhibitor is clinically approved despite efforts. Developing such inhibitors is highly desirable. Herein, a docking-based strategy was used to screen the TCM (Traditional Chinese Medicine) database to identify possible IL-1β inhibitors with desirable pharmacological characteristics by targeting the IL-1β/IL-1R interface. Primarily, the docking-based screening was performed by selecting the crucial residues of IL-1β interface to retrieve the potential compounds. Afterwards, the compounds were shortlisted on the basis of binding scores and significant interactions with the crucial residues of IL-1β. Further, to gain insights into the dynamic behavior of the protein–ligand interactions, MD simulations were performed. The analysis suggests that four selected compounds were stabilized in an IL-1β pocket, possibly blocking the formation of an IL-1β/IL-1R complex. This indicates their potential to interfere with the immune response, making them potential therapeutic agents to investigate further.Keywords
Funding Information
- Hunan graduate research innovation project (CX20210679, CX20210685)
- Hunan graduate research innovation project (CX20210679, CX20210685)
- the deanship of scientific research, Taif University (CX20210679, CX20210685)
This publication has 45 references indexed in Scilit:
- Treating inflammation by blocking interleukin-1 in a broad spectrum of diseasesNature Reviews Drug Discovery, 2012
- Sterile inflammation of endothelial cell-derived apoptotic bodies is mediated by interleukin-1αProceedings of the National Academy of Sciences, 2011
- Open Babel: An open chemical toolboxJournal of Cheminformatics, 2011
- Berkeleyones and Related Meroterpenes from a Deep Water Acid Mine Waste Fungus That Inhibit the Production of Interleukin 1-β from Induced InflammasomesJournal of Natural Products, 2011
- TCM Database@Taiwan: The World's Largest Traditional Chinese Medicine Database for Drug Screening In SilicoPLOS ONE, 2011
- Mutant superoxide dismutase 1-induced IL-1β accelerates ALS pathogenesisProceedings of the National Academy of Sciences, 2010
- IL-1β Processing in Host Defense: Beyond the InflammasomesPLOS Pathogens, 2010
- Tobacco Smoke Promotes Lung Tumorigenesis by Triggering IKKβ- and JNK1-Dependent InflammationCancer Cell, 2010
- Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1β-Induced Interleukin 6 Production and the Myeloma Proliferative ComponentMayo Clinic Proceedings, 2009
- A novel heterodimeric cysteine protease is required for interleukin-1βprocessing in monocytesNature, 1992